



## Company Overview

Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combating the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum's first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

[Sign up here](#) to receive notices about press releases and SEC filings.

## Iterum Therapeutics Announces Pricing of \$17.5 Million Upsized Public Offering

Oct 23 2020, 12:02 AM EDT

## UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

Oct 19 2020, 7:10 PM EDT

## Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

Oct 19 2020, 6:00 PM EDT

## Stock Overview

Symbol	ITRM
Exchange	Nasdaq
Market Cap	11.16m
Last Price	\$0.5253
52-Week	\$0.5051 - \$7.19

10/23/2020 04:00 PM EDT

## Investor Relations

[ir@iterumtx.com](mailto:ir@iterumtx.com)

## Management Team

### Corey N. Fishman

Chief Executive Officer

### Michael Dunne, MD

Chief Scientific Officer

### Judith M. Matthews

Chief Financial Officer

### Benjamin M. Pe

Vice President Operations

### John J. White

Vice President Commercial Planning & Business Development

### Tom Loughman, PhD

Vice President and CMC Head

## Iterum Therapeutics plc

200 S Wacker Drive  
Suite 2550  
Chicago, IL 60606  
USA

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.